IFNB1 and relapsing-remitting multiple sclerosis: Relapsing-remitting MS (RRMS), the most common form of the disease mainly affecting young adults with a female to male ratio of ~2.5–3 (3, 4), has been treated by type I interferon beta (IFNβ) for nearly three decades.